SG11201609167RA - Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes - Google Patents
Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetesInfo
- Publication number
- SG11201609167RA SG11201609167RA SG11201609167RA SG11201609167RA SG11201609167RA SG 11201609167R A SG11201609167R A SG 11201609167RA SG 11201609167R A SG11201609167R A SG 11201609167RA SG 11201609167R A SG11201609167R A SG 11201609167RA SG 11201609167R A SG11201609167R A SG 11201609167RA
- Authority
- SG
- Singapore
- Prior art keywords
- diabetes
- diseases
- treatment
- gpr40 modulators
- pyrrolidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989560P | 2014-05-07 | 2014-05-07 | |
| PCT/US2015/029422 WO2015171733A1 (en) | 2014-05-07 | 2015-05-06 | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201609167RA true SG11201609167RA (en) | 2016-12-29 |
Family
ID=53181360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609167RA SG11201609167RA (en) | 2014-05-07 | 2015-05-06 | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10017497B2 (ja) |
| EP (1) | EP3140297B1 (ja) |
| JP (1) | JP6488320B2 (ja) |
| KR (1) | KR20170002543A (ja) |
| CN (1) | CN106458987B (ja) |
| AU (1) | AU2015256038B2 (ja) |
| BR (1) | BR112016025188A2 (ja) |
| CA (1) | CA2948175A1 (ja) |
| EA (1) | EA032290B1 (ja) |
| ES (1) | ES2671402T3 (ja) |
| IL (1) | IL248670B (ja) |
| MX (1) | MX2016014118A (ja) |
| SG (1) | SG11201609167RA (ja) |
| WO (1) | WO2015171733A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| BR112012007979A2 (pt) * | 2009-10-06 | 2016-03-29 | Bristol Myers Squibb Co | moduladores de gpr40 de pirrolidina |
| JP5864177B2 (ja) | 2011-09-15 | 2016-02-17 | 船井電機株式会社 | プロジェクタおよびプロジェクタシステム |
| TW201427971A (zh) * | 2012-11-16 | 2014-07-16 | 必治妥美雅史谷比公司 | 二氫吡唑ｇｐｒ４０調節劑 |
| ES2605856T3 (es) * | 2012-11-16 | 2017-03-16 | Bristol-Myers Squibb Company | Moduladores GPR40 de dihidropirazol |
| MX2015006038A (es) | 2012-11-16 | 2015-08-07 | Squibb Bristol Myers Co | Moduladores de pirrolidina del receptor acoplado a la proteina g (gpr40). |
| EA201590949A1 (ru) * | 2012-11-16 | 2015-08-31 | Бристол-Майерс Сквибб Компани | Дигидропиразольные модуляторы gpr40 |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
-
2015
- 2015-05-06 EP EP15723096.2A patent/EP3140297B1/en active Active
- 2015-05-06 BR BR112016025188A patent/BR112016025188A2/pt not_active Application Discontinuation
- 2015-05-06 EA EA201692216A patent/EA032290B1/ru not_active IP Right Cessation
- 2015-05-06 CN CN201580023783.8A patent/CN106458987B/zh not_active Expired - Fee Related
- 2015-05-06 MX MX2016014118A patent/MX2016014118A/es unknown
- 2015-05-06 WO PCT/US2015/029422 patent/WO2015171733A1/en active Application Filing
- 2015-05-06 JP JP2016566729A patent/JP6488320B2/ja not_active Expired - Fee Related
- 2015-05-06 ES ES15723096.2T patent/ES2671402T3/es active Active
- 2015-05-06 CA CA2948175A patent/CA2948175A1/en not_active Abandoned
- 2015-05-06 US US15/308,428 patent/US10017497B2/en active Active
- 2015-05-06 SG SG11201609167RA patent/SG11201609167RA/en unknown
- 2015-05-06 AU AU2015256038A patent/AU2015256038B2/en not_active Ceased
- 2015-05-06 KR KR1020167033864A patent/KR20170002543A/ko unknown
-
2016
- 2016-11-01 IL IL248670A patent/IL248670B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3140297B1 (en) | 2018-04-11 |
| EA032290B1 (ru) | 2019-05-31 |
| IL248670B (en) | 2019-09-26 |
| AU2015256038A1 (en) | 2016-12-22 |
| ES2671402T3 (es) | 2018-06-06 |
| WO2015171733A1 (en) | 2015-11-12 |
| EP3140297A1 (en) | 2017-03-15 |
| US10017497B2 (en) | 2018-07-10 |
| KR20170002543A (ko) | 2017-01-06 |
| CN106458987B (zh) | 2019-09-24 |
| JP6488320B2 (ja) | 2019-03-20 |
| AU2015256038B2 (en) | 2019-07-11 |
| IL248670A0 (en) | 2017-01-31 |
| JP2017514865A (ja) | 2017-06-08 |
| EA201692216A1 (ru) | 2017-04-28 |
| CN106458987A (zh) | 2017-02-22 |
| MX2016014118A (es) | 2017-02-09 |
| CA2948175A1 (en) | 2015-11-12 |
| US20170217930A1 (en) | 2017-08-03 |
| BR112016025188A2 (pt) | 2017-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180641T1 (hr) | Pirolidinski gpr40 modulatori za liječenje bolesti kao što je dijabetes | |
| EP3212233A4 (en) | Combination therapy for treatment of disease | |
| EP3227330A4 (en) | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases | |
| ZA201703112B (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
| EP3115012A4 (en) | Treatment instrument for endoscope | |
| SG11201705194XA (en) | Pharmaceutical composition for treating diabetes | |
| SI3210973T1 (sl) | Heteroarilne spojine za zdravljenje oftalmičnih bolezni | |
| IL270199A (en) | Peptides for the treatment of diabetes | |
| IL248670B (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| IL249502B (en) | New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins | |
| EP3096775A4 (en) | Socs mimetics for the treatment of diseases | |
| GB201403996D0 (en) | Traditional chinese medicine composition for the treatment of diabetes | |
| HK1259373A1 (zh) | 用於治療糖尿病的藥物製劑 | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| EP3184055A4 (en) | Medical treatment instrument | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| HUE060927T2 (hu) | N,N-bisz-2-merkaptoetil-izoftálamid neurodegeneratív betegségek kezelésére | |
| PT3166604T (pt) | Agentes para o tratamento de doenças infeciosas retrovirais | |
| EP3508474A4 (en) | INNOVATIVE THERAPEUTIC ACTIVE SUBSTANCE FOR DIABETES | |
| AU2015904246A0 (en) | Treatment of diabetes | |
| AU2016901862A0 (en) | Treatment of diabetes | |
| AU2014902075A0 (en) | New Therapeutic Treatment Combination |